COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety, Tolerability, Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in Latent Autoimmune Diabetes in Adults (LADA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00058981
Recruitment Status : Terminated
First Posted : April 24, 2003
Last Update Posted : March 19, 2009
Information provided by:
DeveloGen Israel, Ltd.

Brief Summary:
Randomized, double-blind, parallel-group study to evaluate safety and efficacy of multiple subcutaneous doses of DiaPep277 in patients with Latent Autoimmune Diabetes in Adults (LADA). Study medication will be administered at time 0, 1 and 3 months, and then every 3 months for a total of 8 administrations. The total duration of the trial is 24 months (treatment for 18 months and follow-up for an additional 6 months). Patients will be male or female between the ages of 30 and 65 years, inclusive, within 2 to 60 months of the diagnosis of diabetes mellitus. Subjects must be positive for glutamic acid decarboxylate (GAD) autoantibodies. At the Screen Visit (Visit 2), all subjects will be asked to discontinue their use of all oral antidiabetic medications with the exception of metformin. The subjects will be placed on a stable regimen of insulin and diet (plus metformin if needed). Prior to the Baseline Visit (Visit 3), diabetic control must be achieved by diet and insulin (plus metformin if needed).

Condition or disease Intervention/treatment Phase
Diabetes, Autoimmune Drug: DiaPep277 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety and Tolerability as Well as the Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in LADA Subjects
Study Start Date : October 2002
Actual Primary Completion Date : March 2007
Actual Study Completion Date : May 2007

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

Subjects meeting all of the following inclusion criteria at screening should be considered for admission to the study:

  • The subject has a diagnosis of diabetes mellitus according to WHO classification for more than 2 months and less than 5 years before enrollment.
  • The subject's diabetes has been controlled by diet and insulin (plus metformin if needed) for 2 or more weeks (14 days) prior to the Baseline Visit (Visit 3).
  • The subject is a male or female aged 30 to 65 years. If female and not postmenopausal, the subject is not pregnant and will use effective contraceptive methods throughout the study.
  • The subject is positive for GAD autoantibodies, defined as a level greater than the 99th percentile of the GAD antibody index of a normal control population for the laboratory (e.g., GAD antibody index equal to 0.085).
  • The subject has a fasting C-peptide level 0.30 nmol/L or greater or 0.9 ng/mL at the time of the Screen Visit (Visit 1 or 2).

Exclusion Criteria

Subjects meeting any of the following exclusion criteria at screening will not be enrolled in the study:

  • The subject has any significant diseases or conditions, including psychiatric disorders and substance abuse that, in the opinion of the site investigator, are likely to affect the subject's response to treatment or their ability to complete the study.
  • The subject has a history of any kind of malignant tumor.
  • The subject has secondary diabetes mellitus.
  • Within 2 weeks or 14 days of the Baseline Visit or during randomized treatment, the subject takes an oral anti-diabetic medication other than metformin to treat his/her diabetes.
  • The subject has clinical evidence of any diabetes-related complication that in the opinion of the site investigator would interfere with the subject's participation in and/or completion of the study.
  • The subject has a history of allergy or asthma that in the opinion of the site investigator would interfere with the subject's participation in and completion of the study.
  • The subject has a known immune deficiency from any disease, or a condition associated with an immune deficiency.
  • The subject is receiving immunosuppressive or immunomodulating agents or cytotoxic therapy, or any medication that, in the opinion of the site investigator, might interfere with the study.
  • The subject is a pregnant woman or a woman who is planning to become pregnant.
  • The subject has any of the following:

    • chronic hepatitis or liver cirrhosis, or any other chronic liver disease
    • is known to test positive for hepatitis B antigens or hepatitis C antibodies
    • has abnormal liver function, defined as serum AST or ALT 3 times or more the upper limit of normal
  • The subject is a known or suspected drug abuser.
  • The subject has influenza-like symptoms on the day of dosing.
  • The subject is known to test positive for HIV antibodies.
  • The subject has chronic hematologic disease.
  • The subject has impaired renal function (serum creatinine greater than 1.4 mg/dL).
  • The subject has severe ketonuria (+++ on urine stix testing; ++ on repeated urine stix testing).
  • The subject has a BMI greater than 40kg/m2.
  • The subject has hyperlipidemia (fasting serum triglycerides >1000 mg/dL). Suitable medical therapy for treatment of hyperlipidemia is allowed.
  • The subject has received any investigational drug within 3 months prior to Visit 1.
  • The subject has had a severe blood loss (400 mL or more, e.g., blood donation) within 2 months before the first dosing of the study medication.
  • The subject is a breast-feeding mother or planning to breast-feed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00058981

Layout table for location information
United States, Alabama
University of Alabama at Birmingham Endocrinology Department
Birmingham, Alabama, United States, 35294
United States, Colorado
University of Colorado Hospital Endocrinology Practice
Aurora, Colorado, United States, 80010
United States, Kentucky
University of Kentucky Department of Internal Medicine
Lexington, Kentucky, United States, 40536
United States, Missouri
Washington University School of Medicine Endocrinology/Metabolic Dept
Saint Louis, Missouri, United States, 63110
United States, New York
North Shore Diabetes and Endocrine Associates
New Hyde Park, New York, United States, 11042
United States, Texas
Diabetes & Glandular Disease Research Associates
San Antonio, Texas, United States, 78229-4801
United States, Washington
DVA Puget Sound Health Care System Endocrinology (III) Department
Seattle, Washington, United States, 98108
Sponsors and Collaborators
DeveloGen Israel, Ltd.
Layout table for investigator information
Principal Investigator: Jerry P Palmer, MD University of Washington
Study Director: Dana Elias, PhD DeveloGen Israel, Ltd.
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00058981    
Other Study ID Numbers: 702/PO
First Posted: April 24, 2003    Key Record Dates
Last Update Posted: March 19, 2009
Last Verified: March 2009
Keywords provided by DeveloGen Israel, Ltd.:
latent autoimmune diabetes in adults
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Latent Autoimmune Diabetes in Adults
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases